Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20731986 | 0.81 | USP2 (0.32) | GAAMAPTHSD17B10USP2ALOX15 | |
| SCHEMBL23938017 | 0.78 | USP2 (0.31) | GAAMAPTHSD17B10USP2ALOX15 | |
| SCHEMBL23938072 | 0.74 | HSD17B10 (0.47) | GAAMAPTHSD17B10MAPK1ALOX15 | |
| SCHEMBL23938015 | 0.69 | USP2 (0.33) | GAAMAPTHSD17B10USP2ALOX15 | |
| SCHEMBL23938023 | 0.68 | GAA (0.41) | GAAMAPTHSD17B10MAPK1SMN1; SMN2 | |
| SCHEMBL21066362 | 0.62 | RAB9A (0.35) | SMN1; SMN2PDE10A | |
| SCHEMBL651969 | 0.61 | NUDT1 (0.31) | GAAMAPTHSD17B10USP2ALOX15 | |
| SCHEMBL26848918 | 0.60 | PLAT (0.34) | — | |
| SCHEMBL24588297 | 0.60 | USP2 (0.39) | GAAMAPTHSD17B10USP2ALOX15 | |
| SCHEMBL13801066 | 0.60 | POLB (0.35) | HSD17B10SMN1; SMN2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | GAA 699/4885MAPT 2661/4885HSD17B10 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.